Last SFr.252.50 CHF
Change Today -3.00 / -1.17%
Volume 3.0K
RO On Other Exchanges
SIX Swiss Ex
SIX Swiss Ex
As of 3:52 AM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

roche holding ag-br (RO) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/3/14 - SFr.290.00
52 Week Low
01/30/14 - SFr.234.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ROCHE HOLDING AG-BR (RO)

roche holding ag-br (RO) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Switzerland, European Union, and internationally. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, treatment, and treatment monitoring of diseases. The company provides pharmaceutical products for various therapeutic areas comprising oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, it offers a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for use in doctors’ offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research. The company has a collaboration agreement with Astrazeneca Plc to develop a plasma-based companion diagnostic test to support AZD9291, a drug candidate for treating non-small-cell lung cancer; and a collaboration agreement with AmorChem L.P. to discover novel small molecule disease-modifying therapy for the treatment of myotonic muscular dystrophy 1 or Steinert's disease. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

85,080 Employees
Last Reported Date: 01/30/14
Founded in 1896

roche holding ag-br (RO) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.1M
Compensation as of Fiscal Year 2013.

roche holding ag-br (RO) Key Developments

F. Hoffmann-La Roche Ltd Announces Earnings Results for the Year Ended December 31, 2014; Provides Earnings Guidance for the Fiscal Year 2015

F. Hoffmann-La Roche Ltd. announced earnings results for the year ended December 31, 2014. For the year, the company reported group sales of CHF 47,462 million against CHF 46,780 million a year ago. Core operating profit was CHF 17,636 million against CHF 17,904 million a year ago. Core net income was CHF 12,533 million against CHF 12,526 million a year ago. IFRS net income was CHF 9,535 million against CHF 11,373 million a year ago. Core earnings per share were CHF 14.29 against CHF 14.27 a year ago. Operating free cash flow was CHF 15,930 million against CHF 15,772 million a year ago. Free cash flow was CHF 5.3 billion. Core profit before taxes was CHF 16,520 million. Net income attributable to the shareholders was CHF 9,332 million or CHF 10.81 per diluted share. Operating profit was CHF 14,090 million. Profit before taxes was CHF 12,515 million. Purchase of property, plant and equipment was CHF 2,966 million against CHF 2,451 million a year ago. Purchase of intangible assets was CHF 368 million against CHF 403 million a year ago. The company provided earnings guidance for the year of 2015. For 2015, the company sales expected to grow low-to mid-single digit, at constant exchange rates. Core earnings per share targeted to grow at constant exchange rates ahead of sales.

Roche Renews Health Co-Operation Agreement with Catlab

Roche (Switzerland) has announced the renewal of a co-operation contract with the Spanish Clinical Center (Catlab) for the sixth time. Under the new contract, Roche aims to continue co-operating on the incorporation of innovative medicines in the healthcare services provided by Catlab.

Roche Holding AG Wins EUR 1.4 Million Clinical Chemistry Automation Deal

Swiss University Hospital of Basel has awarded a contract for the delivery of automated instruments for the clinical chemistry laboratory to Roche Diagnostics AG, part of Roche Holding AG. The final value of the deal is some CHF 1.4 million excluding VAT. The contracting authority has received a total of two offers of its open tender.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RO:SW SFr.252.50 CHF -3.00

RO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $23.84 USD -0.54
Gilead Sciences Inc $102.45 USD -2.58
Merck & Co Inc $61.45 USD -1.11
Novartis AG SFr.89.40 CHF +0.70
Pfizer Inc $31.95 USD -0.65
View Industry Companies

Industry Analysis


Industry Average

Valuation RO Industry Range
Price/Earnings 20.8x
Price/Sales 4.5x
Price/Book 12.6x
Price/Cash Flow 16.9x
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-BR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at